<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675779</url>
  </required_header>
  <id_info>
    <org_study_id>204-08</org_study_id>
    <nct_id>NCT00675779</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Atorvastatin in Pelvic Pain Relief in Women With Endometriosis</brief_title>
  <acronym>EndoStatin</acronym>
  <official_title>Comparison of Pain Relief and Inflammatory Status in Women With Surgically Confirmed Endometriosis Treated With Atorvastatin, Oral Contraceptive or Combined Oral Contraceptives and Atorvastatin: Open Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biomet Polska Sp. z.o.o.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether atorvastatin (alone or in combination with
      oral contraceptive) is effective in treatment of pelvic pain and inflammatory response in
      women with endometriosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain relief</measure>
    <time_frame>3,6,12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory status</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Endometriosis</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral contraceptive + atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral contraceptive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive (Mercilon)</intervention_name>
    <description>oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mercilon (Organon Schering-Plough, Poland)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin + oral contraceptive</intervention_name>
    <description>atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Atrox 20 (Biofarm sp. z o.o. , Poznan, Poland)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed written consent

          -  premenopausal women aged 18-45

          -  clinical signs and symptoms of endometriosis for minimum 3 months with endometriosis
             confirmed at laparoscopy or laparotomy within last 4 months - 5 years (preferably with
             histological confirmation)

          -  pain symptoms of moderate intensity (dysmenorrhoea + dyspareunia + nonmenstrual pelvic
             pain &gt; 6 points on Biberoglu &amp; Behrman scale [1981])

          -  no clinical signs of sexually transmitted disease

        Exclusion Criteria:

          -  cancer of the ovary, adrenals, endometrium, uterine cervix, breasts

          -  pregnancy or lactation

          -  unexplained uterine/cervical bleeding

          -  hormonal therapy within last 3 months (for GnRH analogs 6 months)

          -  irregular menses (&gt; 35 days) or secondary amenorrhoea (&gt;3 months)

          -  other chronic disease affecting pelvic or abdominal cavity (including PID, ulcerating
             colitis , Crohn's disease, recurrent interstitial cystitis)

          -  sexually transmitted disease (gonorrhoea, Chlamydia)

          -  uncontrolled diabetes mellitus type I or II, VTE or other contraindications to
             medicine used in the study

          -  chronic therapy with CYP3A4 inhibitors (including ketoconazole, erythromycin and
             others)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni J Duleba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davies, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leszek Pawelczyk, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Poznan University of Medical Sciences, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences, Department of Gynecology and Obstetrics</name>
      <address>
        <city>Poznan</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <last_update_submitted>May 9, 2008</last_update_submitted>
  <last_update_submitted_qc>May 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Z. Spaczynski, MD PhD</name_title>
    <organization>Poznan University of Medical Sciences</organization>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>oral</keyword>
  <keyword>contraception</keyword>
  <keyword>pain</keyword>
  <keyword>relief</keyword>
  <keyword>pelvic pain in women with endometriosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Dacuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

